We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Blood Test Can Identify and Confirm Neurodegenerative Disease

By LabMedica International staff writers
Posted on 15 Jul 2022

Neurological disease presents in many forms, and today, confirmation of disease is often complex and challenging. More...

When neurons are damaged, proteins called neurofilaments are released and are detectable in blood. One of three main neurofilament types, Neurofilament Light Chain (NfL) has been the most widely studied in research settings, but a reliable NfL test has not been widely available for patient care. Now, the first widely accessible NfL test that provides direct evidence of neurodegeneration and neuronal injury is expected to provide significant benefits in supporting more effective diagnosis and treatment of many disorders.

LabCorp Diagnostics (Burlington, NC, USA) has launched a new NfL blood test that will allow doctors to identify and verify signs of neurodegenerative disease, enabling physicians to provide a more effective and efficient path to diagnosis and treatment for patients. Elevated NfL levels signal neuronal injury, whether from diseases like multiple sclerosis, Alzheimer’s and Parkinson’s, or from brain injury, such as with concussion. The new NfL test is performed from a standard blood collection that can be done at a hospital, physician’s office or at any of Labcorp’s nearly 2,000 patient service centers.

“NfL is a simple, objective blood test that provides direct evidence of neuronal damage,” said Dr. Brian Caveney, chief medical officer and President, Labcorp Diagnostics. “In making this test widely available, Labcorp is supporting neurologists with a tool they’ve been asking for that enables faster diagnoses, better treatment decisions and improved patient care. It’s a major step forward in the monitoring and identification of patients with neuronal injury due to disease or trauma.”

“Importantly, NfL isn’t specific to one disease, but it is highly specific to neuronal damage from a wide variety of causes, from Alzheimer’s and multiple sclerosis to concussion and physical injury. This test will be impactful in helping many patients,” said Dr. Joseph Volpe, neurology business segment and discipline director at Labcorp. “Serial use of NfL testing can help doctors to follow trends that indicate the effectiveness of medicines or therapies, or whether there is continued injury or disease progression.”

Related Links:
LabCorp Diagnostics 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
POC Immunoassay Analyzer
Procise DX
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.